We are live on ! Find out more
BIOR

Biora Therapeutics, Inc. Common Stock
BIOR

Delisted

BIOR was delisted on the 10th of December, 2024.

Back to rankings

39 hedge funds and large institutions have $83.1M invested in Biora Therapeutics, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

120% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 10

75% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 4

44% more funds holding

Funds holding: 27 → 39 (+12)

2% less capital invested

Capital invested by funds: $84.5M → $83.1M (-$1.44M)

Holders
39
Holders Change
+12
Holders Change %
+44.44%
% of All Funds
0.79%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
22
Increased
7
Reduced
4
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$3.62M
2
BlackRock
BlackRock
New York
+$905K
3
Northern Trust
Northern Trust
Illinois
+$498K
4
DCM
Driehaus Capital Management
Illinois
+$452K
5
DCM
Dupont Capital Management
Delaware
+$339K

Top Sellers

Rank Fund Capital Flow
1
APM
Avidity Partners Management
Texas
-$2.15M
2
HP
Hound Partners
New York
-$1.99M
3
Citadel Advisors
Citadel Advisors
Florida
-$900K
4
ZP
Zimmer Partners
New York
-$900K
5
Goldman Sachs
Goldman Sachs
New York
-$576K
Name Holding Trade Value Shares
Change 		Change in
Stake
New York State Common Retirement Fund
26
New York State Common Retirement Fund
New York
$55K +$54.3K +24 New
Bank of America
27
Bank of America
North Carolina
$52K +$52K +23 New
JP Morgan Chase
28
JP Morgan Chase
New York
$23K +$24.9K +11 New
AIG
29
American International Group
New York
$19K +$18.1K +8 New
Royal Bank of Canada
30
Royal Bank of Canada
Ontario, Canada
$18K +$18.1K +8 New
Deutsche Bank
31
Deutsche Bank
Germany
$16K +$15.8K +7 New
UBS Group
32
UBS Group
Switzerland
$16K +$15.8K +7 New
TRCT
33
Tower Research Capital (TRC)
New York
$6K +$6.79K +3 New
Morgan Stanley
34
Morgan Stanley
New York
$5K +$4.52K +2 New
Legal & General Group
35
Legal & General Group
United Kingdom
$4K +$4.52K +2 New
AIP
36
Ameritas Investment Partners
Nebraska
$3K +$2.26K +1 New
Millennium Management
37
Millennium Management
New York
$1.07K +$2.26K +1 +0.2%
SFS
38
Sowell Financial Services
Arkansas
$1K – – –
Bank of Montreal
39
Bank of Montreal
Ontario, Canada
$1K +$2.26K +1 New
Citigroup
40
Citigroup
New York
$1K +$2.26K +1 New
APM
41
Avidity Partners Management
Texas
– -$2.15M -955 Closed
HP
42
Hound Partners
New York
– -$1.99M -884 Closed
Citadel Advisors
43
Citadel Advisors
Florida
– -$900K -400 Closed
ZP
44
Zimmer Partners
New York
– -$900K -400 Closed
Goldman Sachs
45
Goldman Sachs
New York
– -$576K -256 Closed
Point72 Asset Management
46
Point72 Asset Management
Connecticut
– -$450K -200 Closed
ECM
47
ExodusPoint Capital Management
New York
– -$143K -64 Closed
PHK
48
Point72 Hong Kong
Hong Kong
– -$80K -36 Closed
Russell Investments Group
49
Russell Investments Group
United Kingdom
– -$9K -4 Closed
US Bancorp
50
US Bancorp
Minnesota
– -$2K -1 Closed
1
2

BIOR Hedge Fund Activity: Q3 2020 in Review

39 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Biora Therapeutics, Inc. Common Stock (BIOR) for Q3 2020, worth a combined $83.1M — down 1.7% from $84.5M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new BIOR positions and 10 closed out — a net gain of 12 holders — while 7 added to existing stakes and 4 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $3.62M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $2.15M sold.

  • 39 institutional investors held Biora Therapeutics, Inc. Common Stock (BIOR) as of Q3 2020, up from 27 in Q2 2020.
  • Funds reported $83.1M of Biora Therapeutics, Inc. Common Stock stock for Q3 2020, down 1.7% quarter-over-quarter.
  • 22 funds opened new Biora Therapeutics, Inc. Common Stock positions in Q3 2020 and 10 closed out, a net change of +12 holders.
  • The largest Biora Therapeutics, Inc. Common Stock buyer in Q3 2020 was Armistice Capital, an estimated $3.62M added.
  • The largest Biora Therapeutics, Inc. Common Stock seller in Q3 2020 was Avidity Partners Management, an estimated $2.15M sold.

Based on aggregated 13F filings for Q3 2020.